Aspire Private Capital’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Aspire Private Capital’s Portfolio SBIO Stock Details SBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-67	Closed	-$2K	–	617
2019 Q1	$2K	Hold	67	–	–	﹤0.01%	450
2018 Q4	$2K	Buy	+67	New	+$2.22K	﹤0.01%	424

Other funds holding SBIO

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return

CCP

Cardan Capital Partners Denver, Colorado $893M AUM 22.82% 1-Year Est. Return

NAM

NTV Asset Management Charleston, West Virginia $1.02B AUM 31.16% 1-Year Est. Return

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

WIA

Wealthstreet Investment Advisors Dallas, Texas $3.71M AUM 13.1% 1-Year Est. Return

Aspire Private Capital's SBIO Position: Q2 2019 in Review

Aspire Private Capital sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q2 2019, closing a stake of 67 shares — an estimated $2K sold.

Aspire Private Capital first reported a position in SBIO in Q4 2018 and held it in 2 quarters. The position peaked at $2K in Q1 2019. 47 funds tracked by Wall St. Rank hold SBIO as of Q2 2019.

Aspire Private Capital reported no remaining ALPS Medical Breakthroughs ETF position as of Q2 2019 after selling out during the quarter.
Aspire Private Capital sold 67 ALPS Medical Breakthroughs ETF shares in Q2 2019, an estimated $2K.
Aspire Private Capital first reported a position in ALPS Medical Breakthroughs ETF in Q4 2018 and held it in 2 quarters.
Aspire Private Capital's ALPS Medical Breakthroughs ETF position peaked at $2K in Q1 2019.
47 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q2 2019.

Based on Aspire Private Capital's 13F filing for Q2 2019, filed 13 Aug 2019.